[Which diagnostic and therapeutic approach to the Zollinger-Ellison syndrome should be adopted in 1990?].
A diagnostic and therapeutic strategy for ZES is proposed based on the vast experience (180 cases) of this rare disease gained at hospital Bichat (Paris, France). The first step is diagnostic and relies essentially a) upon measurements of gastric acid and serum gastrin in the basal state and b) upon the results of secretin test because of the overlap between ZES and duodenal ulcer disease in a large proportion of cases. In sporadic ZES cases, after adequate control of acid overproduction and attempt to localize the tumoral process(es), surgery is indicated (at the exception of patients with advanced metastatic disease). Surgery aims essentially at eradicating gastrinoma(s) as often as possible and whenever it is feasible without endangering patient's life. An apparently definite cure is attained in 60 to 80% in extrapancreatic gastrinoma(s) and 20 to 30% when gastrinomas are located within the pancreas. Liver involvement (25% of ZES cases) remains the major concern and death cause in these patients. Although liver metastases frequently stabilize and sometimes regress upon chemotherapy and chemoembolization, liver transplantation may, in the future, represent the major chance for these patients; but in this frequently slowly evolving condition, the time for liver transplantation is exceptionally difficult to settle.
Service d'Hépato-gastroentérologie, Hôpital Bichat, Paris, France.
M
M
Mignon
G
G
Benhamou
D003937:Diagnosis, Differential; D005745:Gastric Acidity Determination; D015408:Gastrinoma / Q000601:surgery; D005755:Gastrins / Q000032:analysis; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D009377:Multiple Endocrine Neoplasia / Q000175:diagnosis; D010190:Pancreatic Neoplasms / Q000601:surgery; D012633:Secretin; D015043:Zollinger-Ellison Syndrome / Q000175:diagnosis* / Q000601:surgery
D005755:Gastrins; D006635:Histamine H2 Antagonists; D012633:Secretin
Quelles stratégies diagnostique et thérapeutique faut-il adopter en 1990 dans le syndrome de Zollinger-Ellison (SZE)?